PTGX
Protagonist Therapeutics
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
News
- Protagonist Therapeutics received FDA approval for the hepcidin mimetic peptide MIMRYLO (rusfertide) for polycythemia veraAug 31, 2026
- The FDA accepted the NDA and granted Priority Review for rusfertide for polycythemia veraMar 2, 2026
- Protagonist announces Icotrokinra application for approval in plaque psoriasis submitted to European Medicines AgencySep 11, 2025
- Rusfertide receives breakthrough therapy designation for treatment of erythrocytosis in polycythemia vera patientsAug 25, 2025
- Protagonist submits NDA for first icotrokinra, seeking FDA approval to transform plaque psoriasis treatment for adults and adolescentsJul 21, 2025